开放标签的审判叶酸receptor-targeted术中分子成像定位肺鳞状细胞癌。
文章的细节
-
引用
复制到剪贴板 -
夏Predina JD,牛顿广告,L, Corbett C, Connolly C,胫骨M, Sulyok低频,Litzky L, Deshpande C,聂年代,Kularatne SA,低PS, Singhal年代
开放标签的审判叶酸receptor-targeted术中分子成像定位肺鳞状细胞癌。
Oncotarget。2018年2月5日,9 (17):13517 - 13529。doi: 10.18632 / oncotarget.24399。eCollection 2018 3月2。
- PubMed ID
-
29568374 (在PubMed]
- 文摘
-
背景:临床适用性叶酸receptor-targeted术中分子成像(FR-IMI)已经建立手术可切除的肺腺癌。FR-IMI其他肺癌组织学的作用还没有被研究过。在这项研究中,我们评估的可行性在接受肺切除术的患者FR-IMI鳞状细胞癌(癌)。方法:在人类临床试验(NCT02602119), 12个科目与肺癌接受FR-IMI目标的近红外造影剂叶酸receptor-alpha (FRalpha) OTL38。近红外信号和良性肺肿瘤是量化计算tumor-to-background比率(创业)。叶酸receptor-alpha表达特征,病理相关分析来评估OTL38积累的模式。一个探索性的分析来确定病人和病理变量预测肿瘤荧光。结果:13 9癌(9 12学科)术中对近红外荧光显示评价(平均为3.9)。OTL38积累在癌FRalpha-dependent的方式。FR-IMI可靠的本地化结节小1.1厘米,和避免转换为结节胸廓切开术定位在三个科目。 Upon evaluation of patient and histopathologic variables, in situ fluorescence was associated with distance from the pleural surface, and was independent of alternative variables including tumor size and metabolic activity. Conclusions: This work demonstrates that FR-IMI is potentially feasible in 70% of SCC patients, and that molecular imaging can improve localization during minimally invasive pulmonary resection. These findings complement previous data demonstrating that approximately 98% of pulmonary adenocarcinomas are localized during FR-IMI and suggest broad applicability for NSCLC patients undergoing resection.
beplay体育安全吗DrugBank数据引用了这篇文章
- 药物